NCT06659224

The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

The Risk of Developing Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma: A SEER-based Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,631 (actual)
• Sponsor: asmaa salama ibrahim · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Conditions

• Acute Myeloid Leukemia (AML)
• Ewing Sarcoma

Timeline

• Start date: 2000-01-01
• Primary completion: 2021-12-30
• Completion: 2021-12-30
• First posted: 2024-10-26
• Last updated: 2025-07-23

Locations

1 site across 1 country: Egypt